Piramal Structured Credit Opportunities Fund
Piramal Structured Credit Opportunities Fund is a dedicated Piramal Alternatives private-credit vehicle providing structured and performing capital to Indian businesses. Public company disclosures attribute investments to Biodeal Pharmaceuticals, Transaction Solutions International, Nihilent and Neelkanth Subh Ashish Exim; Biodeal’s July 2026 announcement records a full redemption of its 2024 investment with a reported 20%+ IRR.
At a glance
- Founded
- 2020
- Footprint
- Mumbai
- Stage
- Performing and structured private credit; growth and special situations
Research profile
Read the manager in sequence.
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Piramal Structured Credit Opportunities Fund uses a performing and structured private credit; growth and special situations approach across Healthcare and pharmaceuticals, technology, financial services, industrials.
Current evidence
Biodeal Pharmaceuticals announced on 2026-07-29 that its ₹110 crore investment from Piramal Structured Credit Opportunities Fund, made in 2024, was fully redeemed and generated a reported 20%+ IRR. Piramal’s current public site continues to list the fund as a performing-credit vehicle.
Strategy
Performing and structured private credit; growth and special situations
Sector focus
Healthcare and pharmaceuticals, technology, financial services, industrials
Current signal
Biodeal Pharmaceuticals announced on 2026-07-29 that its ₹110 crore investment from Piramal Structured Credit Opportunities Fund, made in 2024, was fully redeemed and generated a reported 20%+ IRR. Piramal’s current public site continues to list the fund as a performing-credit vehicle.
Next step
Need this manager reviewed against your mandate?
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.